Novartis AG opened a 35,000-square-foot radioligand therapy facility in Winter Park, Florida, on January 9. This is the company's fourth U.S. location and forms part of its $23 billion investment strategy in the United States. The facility was built to handle specific, time-sensitive logistics for precision oncology treatments, including Pluvicto and Lutathera.
Separately, on January 6, Barclays upgraded its rating for Novartis AG stock to Equal Weight from Underweight. The bank set a price target of CHF 120. Barclays noted a poor operational outlook for 2026 and stated that the company's "fairly rich" pipeline is mostly reflected in its current valuation and faces competition.
Novartis AG is a global biopharmaceutical company with a strong oncology portfolio. It has over 30 high-value therapies and a growing radioligand therapy pipeline. The company invests in precision oncology, advanced manufacturing, and targeted treatments like Pluvicto and Lutathera to address complex cancer needs worldwide.